Key result
Anthracyclines added to induction regimens for childhood ALL showed no benefit in published studies, despite causing late-onset cardiac morbidity in ~25% of survivors.
Why the study?
Does the addition of anthracyclines to induction regimens improve outcomes or increase cardiotoxicity in children with newly diagnosed acute lymphoblastic leukemia?
Population
Children with newly diagnosed acute lymphoblastic leukemia (ALL)
Comparison
Anthracyclines added to induction regimens vs Induction regimens (VPL) without anthracyclines
Design
Review
Authors
Loading...
Questions anthracycline use in childhood ALL induction; challenges consensus while leaving open need for randomized trials.
Does the addition of anthracyclines to induction regimens improve outcomes or increase cardiotoxicity in children with newly diagnosed acute lymphoblastic leukemia?
The routine use of anthracyclines in induction regimens for childhood ALL should be reevaluated due to the lack of proven benefit and significant risk of late-onset cardiotoxicity.
Messinger et al. (1999) conducted a review in Childhood acute lymphoblastic leukemia (ALL). Anthracyclines vs. Vincristine, prednisone, and L-asparaginase (VPL) without anthracyclines was evaluated on Efficacy and late-onset cardiac morbidity. Anthracyclines added to induction regimens for childhood ALL showed no benefit in published studies, despite causing late-onset cardiac morbidity in ~25% of survivors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: